Drug Search Results
More Filters [+]

BMS-986397

Alternative Names: bms-986397, bms 986397, bms986397, cc-91633, cc91633, cc 91633
Latest Update: 2024-07-08
Latest Update Note: Clinical Trial Update

Product Description

BMS-986397 is being developed by Bristol-Myer Squibb for the treatment of Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04951778?term=BMS-986397&draw=2&rank=1)

Mechanisms of Action: CK1a Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BMS-986397

Countries in Clinic: Australia, Canada, Spain, United Kingdom, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Acute Myeloid Leukemia|Myelodysplastic Syndrome|Preleukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CC-91633-AML-001

P1

Recruiting

Acute Myeloid Leukemia|Myelodysplastic Syndrome|Preleukemia

2026-05-05

Recent News Events